BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?

BACKGROUND: Benefit from temozolomide (TMZ) chemotherapy in the treatment of isocitrate dehydrogenase (IDH)-wildtype glioblastoma is essentially limited to patients with O(6)-methylguanine DNA methyltransferase (MGMT) promoter-methylated tumors. Recent studies suggest that the impact of the MGMT sta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Gramatzki, Dorothee, Felsberg, Jörg, Hentschel, Bettina, Wolter, Marietta, Schackert, Gabriele, Westphal, Manfred, Regli, Luca, Thon, Niklas, Tatagiba, Marcos, Wick, Wolfgang, Schlegel, Uwe, Krex, Dietmar, Matschke, Jakob, Roth, Patrick, Suresh, Marian, Kamp, Marcel, Rushing, Elisabeth, Pietsch, Torsten, von Deimling, Andreas, Sabel, Michael, Loeffler, Markus, Weller, Michael, Reifenberger, Guido
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2020
Materias:
Biomarkers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650336/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.056
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares